| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Navy Medical Oncology Branch [T. M., H. K. O., J. L. M., R. P., J. V., J. D. M., A. F. G.], Surgery Branch [H. P.], and Biostatistics and Data Management Section [S. M. S.], National Cancer Institute and National Naval Medical Center, Bethesda, Maryland 20889-5105
We analyzed 66 non-small cell lung cancer cell lines for mutations at codons 12, 13, and 61 of all three ras genes and correlated the findings with patient survival. We used designed restriction fragment-length polymorphisms to detect mutations after amplification of ras-specific sequences by the polymerase chain reaction. We found 19 mutations of ras genes (29%), and 11 of these 19 (58%) were at codon 12 of the K-ras gene. By univariate analysis, the presence of any ras mutation in cell lines from patients who received curative intent treatment was associated with a shorter survival (P2 = 0.002). For patients who received only palliative treatment, detection of K-ras mutations at codon 12 was associated with a shortened survival (P2 = 0.0103), but this analysis was not statistically significant for the group with any ras mutation (P2 = 0.093). The Cox proportional hazards model also predicted a higher risk for patients with any type of ras mutations. We conclude that ras mutations, present in a subset of non-small cell lung cancers, are independently associated with the shortened survival of patients, irrespective of treatment intent.
1 Present address: Second Department of Surgery, University of Occupational and Environmental Health, Iseigaoka 1-1, Yahatanishi-ku, Kitakyushu 807, Japan. To whom requests for reprints should be addressed.
Received 6/25/91. Accepted 7/30/91.
This article has been cited by other articles:
|
|
 |
|
  M. Ray, R. Salgia, and E. E. Vokes The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer Oncologist, November 1, 2009; 14(11): 1116 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Floyd, C. L. Farnsworth, N. D. Kock, M. C. Mizesko, J. L. Little, S. T. Dance, J. Everitt, J. Tichelaar, J. A. Whitsett, and M. S. Miller Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model Carcinogenesis, December 1, 2005; 26(12): 2196 - 2206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Lee, S.-H. Oh, J. K. Woo, W.-Y. Kim, C. S. Van Pelt, R. E. Price, D. Cody, H. Tran, J. M. Pezzuto, R. M. Moriarty, et al. Chemopreventive Effects of Deguelin, a Novel Akt Inhibitor, on Tobacco-Induced Lung Tumorigenesis J Natl Cancer Inst, November 16, 2005; 97(22): 1695 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Han, S. H. Oh, F. Morgillo, J. N. Myers, E. Kim, W. K. Hong, and H.-Y. Lee Hypoxia-inducible Factor 1{alpha} and Antiangiogenic Activity of Farnesyltransferase Inhibitor SCH66336 in Human Aerodigestive Tract Cancer J Natl Cancer Inst, September 7, 2005; 97(17): 1272 - 1286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M.G.M. Appels, J. H. Beijnen, and J. H.M. Schellens Development of Farnesyl Transferase Inhibitors: A Review Oncologist, September 1, 2005; 10(8): 565 - 578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Lee, S.-H. Oh, Y.-A. Suh, J. H. Baek, V. Papadimitrakopoulou, S. Huang, and W. K. Hong Response of Non-Small Cell Lung Cancer Cells to the Inhibitors of Phosphatidylinositol 3-Kinase/Akt- and MAPK Kinase 4/c-Jun NH2-Terminal Kinase Pathways: An Effective Therapeutic Strategy for Lung Cancer Clin. Cancer Res., August 15, 2005; 11(16): 6065 - 6074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Thomas, L. A. Doyle, and M. J. Edelman Lung Cancer in Women: Emerging Differences in Epidemiology, Biology, and Therapy Chest, July 1, 2005; 128(1): 370 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, C. Butts, Y. Cormier, G. Goss, R. Inculet, E. Vallieres, et al. Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer N. Engl. J. Med., June 23, 2005; 352(25): 2589 - 2597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Srinivas, D. M. Juroske, S. Kalyankrishna, D. D. Cody, R. E. Price, X.-C. Xu, R. Narayanan, N. L. Weigel, and J. M. Kurie c-Jun N-Terminal Kinase Contributes to Aberrant Retinoid Signaling in Lung Cancer Cells by Phosphorylating and Inducing Proteasomal Degradation of Retinoic Acid Receptor {alpha} Mol. Cell. Biol., February 1, 2005; 25(3): 1054 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, Z. Zhang, Y. Yan, W. J. Lemon, M. LaRegina, C. Morrison, R. Lubet, and M. You A Chemically Induced Model for Squamous Cell Carcinoma of the Lung in Mice: Histopathology and Strain Susceptibility Cancer Res., March 1, 2004; 64(5): 1647 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K M Fong, Y Sekido, A F Gazdar, and J D Minna Lung cancer * 9: Molecular biology of lung cancer: clinical implications Thorax, October 1, 2003; 58(10): 892 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shoji, F. Tanaka, T. Takata, K. Yanagihara, Y. Otake, N. Hanaoka, R. Miyahara, T. Nakagawa, Y. Kawano, S. Ishikawa, et al. Clinical Significance of p21 Expression in Non-Small-Cell Lung Cancer J. Clin. Oncol., September 15, 2002; 20(18): 3865 - 3871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Schiller, S. Adak, R. H. Feins, S. M. Keller, W. A. Fry, R. B. Livingston, M. E. M. Hammond, B. Wolf, L. Sabatini, J. Jett, et al. Lack of Prognostic Significance of p53 and K-ras Mutations in Primary Resected Non-Small-Cell Lung Cancer on E4592: A Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy J. Clin. Oncol., January 15, 2001; 19(2): 448 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Hirsch, W. A. Franklin, A. F. Gazdar, and P. A. Bunn Jr. Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology Clin. Cancer Res., January 1, 2001; 7(1): 5 - 22. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Roelofs, M. C. Mostert, K. Pompe, G. Zafarana, M. van Oorschot, R. J. H. L. M. van Gurp, A. J. M. Gillis, H. Stoop, B. Beverloo, J. W. Oosterhuis, et al. Restricted 12p Amplification and RAS Mutation in Human Germ Cell Tumors of the Adult Testis Am. J. Pathol., October 1, 2000; 157(4): 1155 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Fong, Y. Sekido, and J. D. Minna MOLECULAR PATHOGENESIS OF LUNG CANCER J. Thorac. Cardiovasc. Surg., December 1, 1999; 118(6): 1136 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Graziano, G. P. Gamble, N. B. Newman, L. Z. Abbott, M. Rooney, S. Mookherjee, M. L. Lamb, L. J. Kohman, and B. J. Poiesz Prognostic Significance of K-ras Codon 12 Mutations in Patients With Resected Stage I and II Non–Small-Cell Lung Cancer J. Clin. Oncol., February 1, 1999; 17(2): 668 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Catzavelos, M.-S. Tsao, G. DeBoer, N. Bhattacharya, F. A. Shepherd, and J. M. Slingerland Reduced Expression of the Cell Cycle Inhibitor p27Kip1 in Non-Small Cell Lung Carcinoma: A Prognostic Factor Independent of Ras Cancer Res., February 1, 1999; 59(3): 684 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Gazdar and A. Virmani Sensitive Methods for the Detection of ras Mutations in Lung Cancer: Some Answers, More Questions Clin. Chem., July 1, 1998; 44(7): 1376 - 1378. [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Heasley, S. Thaler, M. Nicks, B. Price, K. Skorecki, and R. A. Nemenoff Induction of Cytosolic Phospholipase A2 by Oncogenic Ras in Human Non-small Cell Lung Cancer J. Biol. Chem., June 6, 1997; 272(23): 14501 - 14504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Nesbitt, J. B. Putnam Jr, G. L. Walsh, J. A. Roth, and C. F. Mountain Survival in Early-Stage Non--Small Cell Lung Cancer Ann. Thorac. Surg., August 1, 1995; 60(2): 466 - 472. [Abstract] [Full Text]
|
|
|
|
|
|
P. F. Bongiorno, R. I. Whyte, E. J. Lesser, J. H. Moore, M. B. Orringer, and D. G. Beer Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 590 - 595. [Abstract] [Full Text]
|
|
|
|
|
|
R. Rosell, J. Gomez-Codina, C. Camps, J. Maestre, J. Padille, A. Canto, J. L. Mate, S. Li, J. Roig, A. Olazabal, et al. A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer N. Engl. J. Med., January 20, 1994; 330(3): 153 - 158. [Abstract] [Full Text]
|
|
|
|
 |
|
 A.F. Gazdar, S. Bader, J. Hung, Y. Kishimoto, Y. Sekido, K. Sugio, A. Virmani, J. Fleming, D.P. Carbone, and J.D. Minna Molecular Genetic Changes Found in Human Lung Cancer and Its Precursor Lesions Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 565 - 572. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Roth Molecular Surgery for Cancer Arch Surg, November 1, 1992; 127(11): 1298 - 1302. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
